Restless Legs Syndrome (RLS), also known as Willis-Ekbom disease, is a common neurological disorder affecting approximately 1.5% to 2.7% of the population in its moderate-to-severe form . Characterized by an irresistible urge to move the legs, particularly during periods of rest or at night, RLS significantly impairs sleep quality and overall quality of life. For decades, dopamine agonists were considered the cornerstone of treatment. However, recent updates to clinical practice guidelines have fundamentally transformed the management of this condition, shifting the focus toward safer, more sustainable long-term strategies .
The first critical step in modern RLS management is not the immediate prescription of medication but a thorough assessment of underlying causes and exacerbating factors. The 2024 American Academy of Sleep Medicine (AASM) guidelines emphasize that all patients with clinically significant RLS should undergo regular testing of serum iron studies, specifically ferritin and transferrin saturation . This recommendation stems from a well-established understanding that brain iron deficiency plays a central role in RLS pathophysiology . Testing should be performed in the morning after a 24-hour period without iron-containing supplements or iron-rich foods to ensure accuracy. Supplementation is recommended when ferritin levels fall below 75 ng/mL or transferrin saturation drops below 20%, thresholds that differ from standard population norms . Intravenous ferric carboxymaltose has received a strong recommendation for patients meeting these iron parameters, representing a significant advancement in treatment .
Beyond iron management, clinicians must systematically evaluate and address factors that can exacerbate RLS symptoms. These include alcohol, caffeine, nicotine, and medications such as antihistamines, certain antidepressants (particularly serotonergic agents), and antidopaminergic drugs . Untreated obstructive sleep apnea should also be considered and managed appropriately. For many patients, these simple interventions—such as eliminating evening caffeine or adjusting problematic medications—can provide meaningful relief without the need for pharmacologic therapy .
Nonpharmacologic approaches form an essential foundation of RLS management, particularly for patients who prefer to avoid medication or who have mild symptoms. Regular, moderate exercise has demonstrated significant benefits, with studies showing that consistent morning exercise can reduce symptom severity while evening exertion may worsen symptoms . Yoga and tai chi have shown particular promise; a 2020 randomized controlled trial found that a 12-week yoga program produced improvements in RLS symptoms comparable to medication but without associated side effects . Other helpful strategies include leg massage, warm baths before bedtime, and the application of heat or cold packs to affected areas . Sleep hygiene practices, such as maintaining consistent sleep-wake schedules and limiting electronic device use before bed, support the overall management of this sleep-related disorder.
When pharmacologic intervention becomes necessary for chronic persistent RLS, the treatment landscape has changed dramatically. The 2024 AASM guidelines represent a paradigm shift, moving away from dopamine agonists as first-line therapy . Previously considered the standard of care, medications such as pramipexole, ropinirole, and rotigotine now carry conditional recommendations against their standard use . This change reflects growing recognition of the serious long-term complications associated with these agents, particularly augmentation—a paradoxical worsening of symptoms that often occurs with chronic use, leading to dose escalation and earlier symptom onset . Impulse control disorders, including pathological gambling and hypersexuality, represent additional risks associated with dopamine agonist therapy.
In their place, alpha-2-delta ligands, commonly known as gabapentinoids, have emerged as the preferred first-line pharmacologic treatment. Gabapentin enacarbil, gabapentin, and pregabalin now carry strong recommendations for the treatment of RLS in adults . These medications offer several advantages: they effectively reduce both sensory symptoms and sleep disturbances, have lower risks of augmentation, and provide sustained efficacy . For patients with comorbid conditions such as end-stage renal disease, gabapentin remains a preferred option, though dosing adjustments are essential .
For patients with refractory RLS—those who do not respond adequately to first-line therapies or who experience significant side effects—more intensive approaches may be required. Combination therapy, often using gabapentinoids together with low-dose dopamine agonists or other agents, can provide synergistic benefit while minimizing individual drug toxicities . Opioid medications, such as extended-release oxycodone, carry conditional recommendations for use in carefully selected patients with severe, treatment-resistant symptoms . However, these agents require meticulous monitoring for risks of dependence, tolerance, and respiratory depression.
Special populations require particular consideration in RLS management. RLS is common during pregnancy, and treatment must carefully weigh maternal symptom relief against potential fetal risks . Nonpharmacologic approaches and iron supplementation should be prioritized in this setting. Children with RLS may benefit from ferrous sulfate supplementation when iron studies indicate deficiency, though the evidence base in pediatric populations remains limited . Patients with end-stage renal disease represent another vulnerable group, with specific recommendations supporting gabapentin, intravenous iron sucrose, and vitamin C based on individual iron parameters .
The global applicability of these updated guidelines has been examined by the World Sleep Society, which surveyed 53 national sleep societies across all inhabited continents . While the AASM guidelines received broad international support, regional variations in medication availability, regulatory restrictions, and treatment traditions necessitate context-specific adaptation. Notably, the recommendation to avoid dopamine agonists generated disagreement in some regions, highlighting the ongoing need for nuanced, culturally sensitive implementation strategies .
The management of restless legs syndrome has evolved substantially from a dopamine-centric approach to a more sophisticated, patient-centered model. Modern care begins with identification and correction of iron deficiency, proceeds through lifestyle modifications and nonpharmacologic interventions, and reserves pharmacologic treatment for those with persistent symptoms. When medications are needed, gabapentinoids have supplanted dopamine agonists as the preferred first-line agents, reflecting a commitment to long-term safety and sustained efficacy. By embracing this updated paradigm, clinicians can offer their patients effective symptom control while minimizing the risks that historically complicated RLS treatment.